CRDF News and Press, Cardiff Oncology Inc. From 02/24/22

Cardiff Oncology press release (NASDAQ:CRDF): Q4 GAAP EPS of -$0.23 misses by $0.06. Revenue of $0.13M (+8.3% Y/Y) beats by $0.1M. CEO comment: "Looking ahead, we are eager to continue exploring synergistic combinations with onvansertib, which include DNA damaging agents, microtubule inhibito...

Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights - Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer program continues to show an objective response rate and median progression-free survival that substantially exceed those...

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO , Jan. 31, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for ...

Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference PR Newswire SAN DIEGO , Jan. 20, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment option...

Tech and biotech stocks on the Nasdaq Stock Market have been taking a beating lately. Narrative-driven growth stocks have fallen out of favor since the start of last December due to the uncertainty created by sky-high inflation rates, the omicron variant, and the Federal Reserve's possi...

Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival - 12 of 35 (34%) patients treated per protocol at the recommended Phase 2 dose (RP2D) in combination w...

Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs - Dr. Smeal has over 20 years of industry experience developing targeted therapies and previously served as CSO of Cancer Biology at Eli...

Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium - Conference call and webcast...

Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference PR Newswire SAN DIEGO , Jan. 4, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for...

Cardiff has one asset, onvansertib, a PLK1 inhibitor which has performed well in the clinic thus far in second line KRAS-mutated mCRC. Pfizer made a recent $15m investment and will get a first look at data. The response rate looks promising to date but the data is not yet mature. ...